Also Known As
Lipoprotein little a
Lp(a)
Formal Name
Lipoprotein (a)
This article was last reviewed on
This article waslast modified on November 5, 2017.
At a Glance
Why Get Tested?

To give your health practitioner additional information about your risk of developing heart disease; as part of a targeted screen for cardiovascular disease (CVD)

When To Get Tested?

When you have a family history of CVD at a young age; when you have heart disease or have had a heart attack or stroke but your lipid profile is normal or shows only mildly elevated cholesterol and/or low-density lipoprotein cholesterol (LDL-C)

Sample Required?

A blood sample drawn from a vein in your arm

Test Preparation Needed?

None; however, Lp(a) is often performed at the same time as a lipid profile and fasting for 9-12 hours may be required for the lipid profile.

You may be able to find your test results on your laboratory's website or patient portal. However, you are currently at Lab Tests Online. You may have been directed here by your lab's website in order to provide you with background information about the test(s) you had performed. You will need to return to your lab's website or portal, or contact your healthcare practitioner in order to obtain your test results.

Lab Tests Online is an award-winning patient education website offering information on laboratory tests. The content on the site, which has been reviewed by laboratory scientists and other medical professionals, provides general explanations of what results might mean for each test listed on the site, such as what a high or low value might suggest to your healthcare practitioner about your health or medical condition.

The reference ranges for your tests can be found on your laboratory report. They are typically found to the right of your results.

If you do not have your lab report, consult your healthcare provider or the laboratory that performed the test(s) to obtain the reference range.

Laboratory test results are not meaningful by themselves. Their meaning comes from comparison to reference ranges. Reference ranges are the values expected for a healthy person. They are sometimes called "normal" values. By comparing your test results with reference values, you and your healthcare provider can see if any of your test results fall outside the range of expected values. Values that are outside expected ranges can provide clues to help identify possible conditions or diseases.

While accuracy of laboratory testing has significantly evolved over the past few decades, some lab-to-lab variability can occur due to differences in testing equipment, chemical reagents, and techniques. This is a reason why so few reference ranges are provided on this site. It is important to know that you must use the range supplied by the laboratory that performed your test to evaluate whether your results are "within normal limits."

For more information, please read the article Reference Ranges and What They Mean.

What is being tested?

Lipoprotein (a) or Lp(a) is one type of lipoprotein that carries cholesterol in the blood. It is similar to low-density lipoprotein (LDL, the "bad" cholesterol) in that it contains a single apolipoprotein B protein along with cholesterol and other lipids. This test measures the amount of Lp(a) in the blood to help evaluate a person's risk of developing cardiovascular disease (CVD).

Like LDL, Lp(a) is considered a risk factor for CVD. The amount of Lp(a) that a person has is genetically determined and remains relatively constant over an individual's lifetime. A high level of Lp(a) is thought to contribute to a person's overall risk of CVD, making this test potentially useful as a cardiovascular risk marker.

The protein portion of Lp(a) consists of:

  • Apolipoprotein B (Apo B) – a protein that is involved in the metabolism of lipids and is the main protein constituent of lipoproteins such as LDL and very low-density lipoprotein (VLDL)
  • Apolipoprotein(a) – A second protein component, called apolipoprotein(a), which is attached to the Apo B. Apolipoprotein(a) has an unusual structure and is thought to inhibit clots from being broken down normally. The size of the apolipoprotein(a) portion of Lp(a) varies in size from person to person and tends to be smaller in Caucasians than in those of African ancestry. The significance of the variation in size in contributing to CVD risk is complex, but there is some evidence that smaller size increases risk. Most Lp(a) tests do not measure the size of apolipoprotein(a), however. They measure and report only the level of Lp(a) in blood.

Since about 50% of the people who have heart attacks have a normal cholesterol level, researchers have sought other factors that may have an influence on heart disease. It is thought that Lp(a) may be one such factor. Lp(a) has two potential ways to contribute. First, since Lp(a) can promote the uptake of LDL into blood vessel walls, it may promote the development of atherosclerotic plaque on the walls of blood vessels. Secondly, since apo(a) has a structure that can inhibit enzymes that dissolve clots, Lp(a) may promote accumulation of clots in the arteries. For these reasons, Lp(a) may be more atherogenic than LDL.

How is the sample collected for testing?

A blood sample is obtained by inserting a needle into a vein in the arm.

Is any test preparation needed to ensure the quality of the sample?

No test preparation is needed; however, since this test may be performed at the same time as a lipid profile, fasting for 9-12 hours may be required.

Accordion Title
Common Questions
  • How is it used?

    The Lp(a) test is used to identify an elevated level of lipoprotein (a) as a possible risk factor in the development of cardiovascular disease (CVD). The test may be used in conjunction with a routine lipid profile to provide additional information about a person's risk for CVD.

    The Lp(a) level is genetically determined and remains relatively constant over an individual's lifetime. Since it is usually not affected by lifestyle changes or by most drugs, it is not the target of therapy. Instead, when Lp(a) is high, the presence of this added risk factor may suggest the need for more aggressive treatment of other, more treatable risk factors such as an elevated low-density lipoprotein (LDL).

  • When is it ordered?

    Lp(a) is not routinely ordered as part of a lipid profile. However, it may be ordered, along with other lipid tests, when an individual has a strong family history of CVD at a young age that is not explained by high LDL or low HDL.

    Some health practitioners may also order these tests when:

    • A person has existing heart or vascular disease, especially those individuals who have healthy lipid levels or ones that are only mildly elevated
    • Someone may have an inherited predisposition for high cholesterol level
    • A person has had a stroke or heart attack but has normal or only mildly elevated lipids
  • What does the test result mean?

    A high Lp(a) level may increase a person's risk for developing CVD and cerebral vascular disease. High Lp(a) can occur in people with a normal lipid profile. An elevated level of Lp(a) is thought to contribute to risk of heart disease independently of other lipids.

    The level of Lp(a) is genetically determined and is not easily modified by lifestyle changes or drugs. However, some non-genetic conditions may also lead to elevated Lp(a). These include estrogen depletion, familial hypercholesterolemia, severe hypothyroidism, uncontrolled diabetes, chronic renal failure, and nephrotic syndrome.

    There are no known problems associated with low Lp(a). Many individuals have no detectable Lp(a) in their blood.

  • Is there anything else I should know?

    In rare cases, an Lp(a) level may be ordered when a woman is postmenopausal to see if elevations in Lp(a), tied to decreasing estrogen levels, have significantly increased her risk of developing CVD.

    Lp(a) is not a routinely ordered test. A National Cholesterol Education Program (NCEP) guideline, the Adult Treatment Panel III, acknowledged the possible usefulness of Lp(a), but it did not recommend widespread screening. The National Academy of Clinical Biochemistry (NACB) guidelines for emerging biomarkers of CVD and stroke also recommend testing for individuals with a strong family history of premature atherosclerotic heart disease and/or high lipid levels (hyperlipidemia), or those with intermediate cardiovascular risk, but do not recommend general screening.

    This is partially due to the fact that Lp(a) levels are genetically determined and difficult to change. Niacin and estrogen (for postmenopausal women) have been shown to lower Lp(a) levels a small amount, but their effect appears to be short-term and it is not known if lowering Lp(a) actually lowers risk. Experts are currently not recommending drug treatments for elevated Lp(a), but some are suggesting that those with elevated Lp(a) should be especially vigilant about lowering their low-density lipoprotein (LDL – the "bad" cholesterol), which may help lower their overall risk.

    In general, lipids should not be measured during a fever or major infection, within four weeks of an acute myocardial infarction (heart attack), a stroke, or major surgery, right after excessive alcohol intake, with severely uncontrolled diabetes, when a woman is pregnant, or during rapid weight loss.

  • Why would my doctor want to order an Lp(a) more than once?

    Typically, the Lp(a) level is only tested once because it is usually fairly constant. Occasionally, your doctor may order a second Lp(a) to confirm the initial level, especially if it was measured when you were ill, to see if your risk has increased significantly after menopause, or (rarely) to monitor the effects of treatment.

  • Can I have an Lp(a) test done in my doctor's office?

    The Lp(a) test requires specialized equipment to perform and is usually performed in a laboratory. Your sample may be sent to a reference laboratory for testing.

  • If Lp(a) levels don't really change over my lifetime, why would my doctor prescribe treatment?
    Although Lp(a) levels do not typically respond to treatment, if you have other additional cardiovascular risk factors, your doctor may want to treat these factors to help lower your overall risk.
View Sources

Sources Used in Current Review

Subhi, Y. (Updated 2014 April 1). Lipoprotein (a). Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/2088118-overview through http://emedicine.medscape.com. Accessed April 2014.

Ye, Z. et. al. (2014). The Association Between Circulating Lipoprotein(a) and Type 2 Diabetes Is It Causal? Medscape Multispecialty from Diabetes. 2014;63(1):332-342 [On-line information]. Available online at http://www.medscape.com/viewarticle/818745 through http://www.medscape.com. Accessed April 2014.

Voora, D. (2012 December 12). Should We Test Lipoprotein(a) to Predict Risk for Atherosclerosis? Medscape Multispecialty [On-line information]. Available online at http://www.medscape.com/viewarticle/775752 through http://www.medscape.com. Accessed April 2014.

Boudi, F. and Ahsan, C. (Updated 2013 December 5). Risk Factors for Coronary Artery Disease. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/164163-overview through http://emedicine.medscape.com. Accessed May 2014.

Zieve, D. (2012 June 4). Lipoprotein-a. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/007262.htm through http://www.nlm.nih.gov. Accessed April 2014.

(© 1995–2014). Lipoprotein (a), Serum. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/81558 through http://www.mayomedicallaboratories.com. Accessed May 2014.

Delgado, J. et. al. (2014 March 14). Cardiovascular Disease (Non-traditional Risk Markers) - Risk Markers - CVD (Non-traditional). ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/CVDRiskMarkerNontrad.html?client_ID=LTD through http://www.arupconsult.com. Accessed May 2014.

Stone, N. et. al. (2013 November 12). 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation. 2013;00:000–000. [On-line information]. Available online at http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a through http://circ.ahajournals.org. Accessed May 2014

Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 112-116.

Malaguarnera M, et. al. Lipoprotein(a) in Cardiovascular Diseases. Biomed Res Int. 2013; 2013: 650989. Published online Dec 30, 2012. Available online at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591100/ through http://www.ncbi.nlm.nih.gov. Accessed June 2014.

Jane Hoover-Plow and Menggui Huang. Lipoprotein(a) Metabolism: Potential Sites for Therapeutic Targets. Metabolism. Apr 2013; 62(4): 479–491. Available online at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547132/ through http://www.ncbi.nlm.nih.gov. Accessed June 2014.

Sources Used in Previous Reviews

Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

Spengler, R. (2002 May 14, Updated). What is lipoprotein(a)? St. Joseph Health System, Health Library [On-line information]. Available online at http://www.sjo.org/library/healthguide/MedicalTests/topic.asp?hwid=tv6799abc through http://www.sjo.org.

Paxton, A. (2002 July). One Year Later, Cholesterol Guidelines Sinking In. In the News, CAP Today Feature Story [On-line article]. Available online at http://www.cap.org/captoday/archive/2002/cholesterol_guidelines_feature.html through http://www.cap.org.

Lipoprotein(a). ARUP's Guide to Clinical Laboratory Testing (CLT) [On-line information]. Available online at http://www.aruplab.com/guides/clt/tests/clt_a48b.htm#1141226 through http://www.aruplab.com.

Sih, I, Contributor. Chapter 63. Lipoprotein Disorders. The Merck Manual of Geriatrics, Section 8: Metabolic and Endocrine Disorders [On-line information]. Available online at http://www.merck.com/pubs/mm_geriatrics/sec8/ch63.htm through http://www.merck.com.

(2000 July 21). Genetics of Coronary Heart Disease. WebMD Health [On-line information]. Available online at http://my.webmd.com/content/article/1675.50290 through http://my.webmd.com.

Apgar, B. (1999 February 15). Oral vs. Transdermal HRT to Reduce Lipoprotein(a) Levels. American Family Physician, Tips from Other Journals [On-line Journal]. Available online at http://www.aafp.org/afp/990215ap/tips.html#Oral through http://www.aafp.org.

Stewart, C. (2001 February 8). Lecture 6: Cholesterol and Lipoproteins. Lecture notes, Biol 366, Univ at Albany, NY [On-line lecture]. PDF available for download at http://www.albany.edu/faculty/cs812/bio366/L06_lipoproteins.pdf through http://www.albany.edu/.

Lipoprotein Structure and Function. Cardiovascular Chemistry Group at Texas A&M University [Website information]. Available online at http://www.chem.tamu.edu/rgroup/macfarlane/problem3.htm through http://www.chem.tamu.edu.

Simon lecture, transcribed by Jessy (2001 December 14). Cardiology 35:Lipids and CVD. SUNY Stony Brook School of Medicine Class of 2004 [On-line lecture notes]. Available online at http://www.stonybrookmed.com/noteservice/2004/Lectures/cardio/cardio35.doc through http://www.stonybrookmed.com.

Pagana, Kathleen D. & Pagana, Timothy J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO., Pp 110-114.

Clarke, W. and Dufour, D. R., Editors (2006). Contemporary Practice in Clinical Chemistry, AACC Press, Washington, DC. Winter, W. and Harris, N. Chapter 21: Lipoprotein Disorders, pp 251-259.

Harrison's Principles of Internal Medicine, 16th edition. Kasper, Braunwald, Fauci, Hauser, Longo, Jameson, eds. McGraw Hill: 2005.

(September 1999) The Cleveland Clinic, Center for Continuing Education, Cleveland Clinic Journal of Medicine: Should One Routinely Screen for Lipoprotein (a)? [Online information, accessed August 2007). Available online at http://clevelandclinicmeded.com/ccjm/sept1999/ccjmoneminutesep99.htm through http://clevelandclinicmeded.com.

(September 2006) High Lipoprotein(a) Levels Plus High LDL Increases CVD Risk in Women. Nainggolan L. Medscape Medical News (online information, accessed August 2007). Available online at http://www.medscape.com/viewarticle/544893 through http://www.medscape.com.

Suk Danik J; Rifai N; Buring JE; Ridker PM. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. 2006; 296(11):1363-70. Available online at http://www.medscape.com/medline/abstract/16985228 through http://www.medscape.com. Accessed Sept 2007.

Zieve, D. and Dugdale, D. (Updated 2010 May 23). Lipoprotein-a. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/007262.htm. Accessed September 2010.

Delgado, J. et. al. (Updated 2010 April). Cardiovascular Disease (Non-traditional Risk Markers) - Risk Markers - CVD (Non-traditional). ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/CVDRiskMarkerNontrad.html?client_ID=LTD through http://www.arupconsult.com. Accessed September 2010.

(© 1995–2010). Unit Code 81558: Lipoprotein (a), Serum. Mayo Clinic, Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/81558 through http://www.mayomedicallaboratories.com. Accessed September 2010.

Myers, G. Editor (© 2009). Emerging CV Risk Factors. The National Academy of Clinical Biochemistry, Laboratory Medicine Practice Guidelines, Emerging Biomarkers for Primary Prevention of Cardiovascular Disease and Stroke [On-line information]. Available online at http://www.aacc.org/members/nacb/LMPG/OnlineGuide/PublishedGuidelines/risk/Pages/default.aspx through http://www.aacc.org. Accessed September 2010.

Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 110-114.

Clarke, W. and Dufour, D. R., Editors (© 2006). Contemporary Practice in Clinical Chemistry: AACC Press, Washington, DC. Pp 254.

Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 678-681.

Henry's Clinical Diagnosis and Management by Laboratory Methods. 21st ed. McPherson R, Pincus M, eds. Philadelphia, PA: Saunders Elsevier: 2007, Pp 202-203.

Jill Rubin, Thomas A. Pearson, Roberta G. Reed, and Lars Berglund. Fluorescence-based, Nonradioactive Method for Efficient Detection of the Pentanucleotide Repeat (TTTTA)n Polymorphism in the Apolipoprotein(a) Gene. Clinical Chemistry Oct 2001; 47: 1758 - 1762.

Ask a Laboratory Scientist

 

Your questions will be answered by a laboratory scientist as part of a voluntary service provided by one of our partners, the American Society for Clinical Laboratory Science (ASCLS). Click on the Contact a Scientist button below to be re-directed to the ASCLS site to complete a request form. If your question relates to this web site and not to a specific lab test, please submit it via our Contact Us page instead. Thank you.

Contact a Scientist